Risk Factors for Mortality in Day +100 Survivors of Allogeneic HCT

Social and disease- and transplant-related factors

A study of 355 patients identifies risk factors for increased mortality in day +100 survivors after allogeneic hematopoietic stem cell transplantation. The study, led by senior author Betty Hamilton, MD, Associate Director of Cleveland Clinic Cancer Center’s Blood and Marrow Transplant Program, found that particular disease- and transplant-related and social factors predicted survival after 100 days.

Advertising Policy

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy

“Identifying factors that can increase mortality allows us to risk-stratify patients for more careful follow-up and support,” says Dr. Hamilton. “The next step is to focus efforts on improving outcomes for these more vulnerable patients.”